Browse drugs

… relief.Conclusions As a potential chemotherapy companion drug, AK135 potently targets IL-1RAP to block IL-1/IL-33/IL-36-driven infla…

… the antigen-expressing tumor cells in mice. The combination of EVM14 with ICIs significantly enhanced the anti-tumor activity. EVM14…

…days at 4°C) but is not optimal for storage longer than 3 days. CytoChex underperforms in preserving key immune cell populations. TokuKi…

…unctionality, and synergizes with immune checkpoint inhibitors. HCW11-006 represents a promising immunotherapeutic agent capable of induc…

…ctivity of a variety of immune subsets. These data suggest that AC484 therapy can be deployed in the clinic to markedly enhance adopt…

…044768.Reference D’Angelo SP, Araujo DM, Abdul Razak AR, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma…

… cells from the tumor and spleen in the MC38 model treated with INCB177054 ± anti-PD1 using paired scRNA-seq and single cell T-cell recept…

…atients were enrolled based on published data supporting use of rituximab or tocilizumab. Each arm aimed to enroll 15 patients. Primary e…

…n while modulating immunosuppressive regulatory T cell (T reg). HM16390 is a novel, long-acting IL-2 analog engineered with precise bin…

…ed by ORR, DOR, DCR, and PFS. Additionally, pharmacokinetics of IMA203 transgene levels in peripheral blood will be evaluated. The tri…

…rmed on a subset of patients (n=>10), including the addition of BAY2965501, demonstrated synergistic elevation in IFNγ and IL2 production …

…ed favorable CHS-114 mediated anti-tumor remodeling.Conclusions CHS-114 administration to HNSCC patients demonstrates selective depleti…